Kura Oncology shares preclinical data for NSCLC treatment

Betsy Goodfellow | September 29, 2023 | News story | Medical Communications Kura Oncology, NSCLC, Oncology, oncology 

Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl transferase inhibitor (FTI) KO-2806 in combination with KRASG12C inhibitors for the treatment of non-small cell lung cancer (NSCLC).

The findings of this data have been presented at the 5th RAS-Targeted Drug Development Summit in Boston, US.

The company plans to dose its first patient in its phase 1 dose-escalation trial of KO-2806 in the second half of 2023, as well as planning to assess the drug in dose-escalation combination cohorts for the treatment of other advanced solid tumours including clear cell renal cell carcinoma (ccRCC) and KRASg12c NSCLC.

Advertisement

Francis Burrows, PhD, senior vice president of Translational Research at Kura Oncology, commented: “Despite advances with KRAS-targeted therapies, a significant unmet need remains for patients with KRASG12C-mutant NSCLC as acquired resistance occurs early and often. We are highly encouraged by these first preclinical data for KO-2806, which demonstrate the potential for FTIs as a mechanism-based combination agent to enhance antitumor activity of targeted therapies, such as KRASG12C inhibitors.”

Betsy Goodfellow

Related Content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

The Gateway to Local Adoption Series

Latest content